Drug Development

Articles

The test results could potentially be used in the development of COVID-19 vaccines and the screening of convalescent plasma for prophylactic and therapeutic use.

LabCorp Launches Neutralizing Antibody Test for COVID-19 Vaccine Development

Catalent will offer vial filling, packaging capacity, and additional staffing at the site to support the production of the initial 100 million doses of the vaccine candidate to supply the US market beginning in the third quarter of 2020.

Catalent and Moderna Collaborate on Fill/Finish Manufacturing of COVID-19 Vaccine Candidate

The company has expanded its laboratory test portfolio with five new molecular, serology, and functional assays for COVID-19 vaccine and therapy development programs.

PPD to Expand its Laboratory Portfolio for COVID-19 Vaccines and Therapies

Symbiosis Pharmaceutical Services has signed a supply agreement with AstraZeneca for the sterile manufacture of AZD1222, a COVID-19 recombinant adenovirus vaccine, to be used in clinical trials.

Symbiosis, AstraZeneca Sign Supply Agreement for Sterile Vaccine Manufacture

Inovio received a $71-million contract from the US Department of Defense to scale up manufacture of its Cellectra smart device to deliver its DNA vaccine.

Inovio to Scale-Up Manufacture of Intradermal Delivery Device for its COVID-19 Vaccine

The companies are expanding their existing collaboration and license agreement to develop mRNA vaccines for infectious diseases.

Sanofi to Expand Collaboration with Translate Bio

The company will invest EUR 610 million (USD$682 million) into a new vaccine production site and research center in France. 

Sanofi to Invest $682 Million into New Vaccine Sites

Valneva will manufacture the Sabin vaccine strains for clinical trials in its manufacturing facility in Solna, Sweden, using Batavia’s process.

Batavia Biosciences to Partner with Valneva Sweden AB for Polio Vaccine Development

Catalent will provide vial filling and packaging capacity to AstraZeneca at its manufacturing facility in Anagni, Italy, for the large-scale commercial manufacturing of the University of Oxford’s adenovirus vector-based COVID-19 vaccine candidate.

Catalent to Partner with AstraZeneca for COVID-19 Vaccine

Oxford Biomedica, has signed a collaboration agreement with the not-for-profit organization, the Vaccines Manufacturing and Innovation Centre, to provide the UK with its first strategic vaccine development and advanced manufacturing capability.

Formulation and Drug Delivery